Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura.

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Takeda (TSE:4502/NYSE:TAK) today…

Read MoreTakeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura.

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients,…

Read MoreAdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease

New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics,…

Read MoreNew Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease

Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 Gilead Sciences, Inc. (Nasdaq: GILD) and Kite,…

Read MoreGilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc.…

Read MoreGilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA at the North American Cystic Fibrosis Conference

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat…

Read MoreVertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA at the North American Cystic Fibrosis Conference

Seagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and…

Read MoreSeagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting